All In Biotech

Drug Trial Radar · NCT06564246

Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease

Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Sep 18, 2024

Primary completion

Aug 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Tanta UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 17 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • Vonoprazan 20 mg versus Pantoprazole 40 mgDrug

    Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in the measured biomarkerTime frame: Before and after 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Theodore Billiharz Institute for Researchs

    Giza, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.